Ivonescimab

articles: 2
regulatory signals: 0
cases: 0

Articles on ivonescimab

Review 05.11.2026

Ivonescimab plus chemotherapy: overall survival advantage in advanced NSCLC

New combinations may influence first-line standards for advanced NSCLC without oncogenic drivers. Confirmation in broader populations remains the aim of ongoing phase III trials.

#pembrolizumab #sacituzumab tirumotecan #ivonescimab d8miq7k9f04rm.cloudfront.net

Review 05.11.2026

Tarlatamab improved survival in second-line treatment of small cell lung cancer

New approaches to small cell lung cancer require validation in larger trials. Concurrent thoracic radiotherapy with first-line chemoimmunotherapy increased toxicity without a survival benefit.

#ivonescimab #tarlatamab #irinotecan d8miq7k9f04rm.cloudfront.net

Interactions mentioned in the articles

Irinotecan
Pembrolizumab
Sacituzumab tirumotecan
Tarlatamab